Patients with migraine willing to fork out for drug that works well

April 2005
PharmacoEconomics & Outcomes News;4/23/2005, Issue 476, p6
Presents the findings of an online analysis of willingness-to-pay (WTP) for migraine medications among patients in the U.S. Percentage of the patients that experienced greater than 25 migraine attacks per year; Average amount for migraine treatment patients are willing to pay; Factors that contribute to WTP, including attending graduate school.


Related Articles

  • Reference-dependent valuations of risk: Why willingness-to-accept exceeds willingness-to-pay. Viscusi, W.; Huber, Joel // Journal of Risk & Uncertainty;Feb2012, Vol. 44 Issue 1, p19 

    The gap between willingness-to-pay (WTP) and willingness-to-accept (WTA) benefit values typifies situations in which reference points-and direction of movement from reference points-are consequential. Why WTA-WTP discrepancies arise is not well understood. We generalize models of reference...

  • Willingness to pay as a measure of health benefits. Bala, M.V.; Mauskopf, J.A.; Wood, L.L. // PharmacoEconomics;1999, Vol. 15 Issue 1, p9 

    In this paper, we discuss the use of cost-benefit analysis (CBA) for evaluating new healthcare interventions, present the theoretical basis for the use of willingness to pay as a method for valuing benefits in a CBA and describe how to obtain willingness-to-pay (WTP) measures of health benefits...

  • Type 2 diabetes patients' preferences and willingness to pay for lifestyle programs: a discrete choice experiment. Veldwijk, Jorien; Lambooij, Mattijs S.; van Gils, Paul F.; Struijs, Jeroen N.; Smit, Henriëtte A.; de Wit, G. Ardine // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background Participation rates of lifestyle programs among type 2 diabetes mellitus (T2DM) patients are less than optimal around the globe. Whereas research shows notable delays in the development of the disease among lifestyle program participants. Very little is known about the relative...

  • The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. Baji, Petra; Gulácsi, László; Groot, Wim; Pavlova, Milena; Farkas, Miklós // European Journal of Health Economics;Nov2014, Vol. 15 Issue 8, p853 

    We examine the willingness of health care consumers to pay formal fees for health care use and how this willingness to pay is associated with past informal payments. We use data from a survey carried out in Hungary in 2010 among a representative sample of 1,037 respondents. The contingent...

  • Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Thavorncharoensap, Montarat; Teerawattananon, Yot; Natanant, Sirin; Kulpeng, Wantanee; Yothasamut, Jomkwan; Werayingyong, Pitsaphun // ClinicoEconomics & Outcomes Research;2013, Vol. 5, p29 

    Background: This study aims to elicit the value of the willingness to pay (WTP) for a quality-adjusted life year (QALY) and to examine the factors associated with the WTP for a QALY (WTP/QALY) value under the Thai health care setting. Methods: A community-based survey was conducted among 1191...

  • The value of thinly spread QALYs. Mortimer, Duncan // PharmacoEconomics;2006, Vol. 24 Issue 9, p845 

    A number of recent findings from the literature imply that the value of a QALY varies depending on the concentration or dispersion of that QALY over treated individuals. Given that funding decisions are currently made under either the assumption of distributive-neutrality or some combination of...

  • Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada: An Analysis from the C-SIRIUS Trial. Rinfret, Stéphane; Cohen, David J.; Tahami Monfared, Amir A.; LeLorier, Jacques; Mireault, Jean; Schampaert, Erick // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 3, p159 

    BACKGROUND: The cost effectiveness of drug-eluting stents in Canada is debated and deserves further evaluation in high-risk patients. METHODS: We performed an economic analysis from the third-party payer perspective based on the clinical results and resource-utilization data of the C-SIRIUS...

  • Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine. Bishai, David; Brice, Roger; Girod, Isabelle; Saleh, Aneta; Ehreth, Jenifer // PharmacoEconomics;2007, Vol. 25 Issue 2, p143 

    Objective: To estimate the willingness of parents in France and Germany to pay for meningococcal conjugate vaccines for their teenage children.Methods: A conjoint analysis survey was administered to parents who had received counselling on the nature and risks of...

  • Willingness to pay for a QALY: theoretical and methodological issues. Gyrd-Hansen, Dorte // PharmacoEconomics;2005, Vol. 23 Issue 5, p423 

    What is a QALY worth in monetary units? This paper presents the main arguments in the literature regarding the obstacles involved in establishing one unique willingness to pay (WTP) estimate for the value of a QALY. To directly translate QALYs into monetary units, and in this manner translate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics